What’s New in PET/CT
AI in PET/CT: Detecting Multiple Cancers with Whole-Body Imaging
Research presented at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting explored AI-assisted detection of six cancer types using PET/CT images. The findings describe a research setting and do not establish that the tool is available on SMS systems or suitable for every clinical setting.
Why AI is needed in PET/CT cancer detection
Traditional AI cancer models have been limited by small datasets and narrow clinical focus, typically detecting just one malignancy type at a time, using a single radiotracer. According to Kevin H. Leung, PhD, research associate at Johns Hopkins University School of Medicine, this presents a serious limitation:
“Automatic detection and characterization of cancer are important clinical needs to enable early treatment.”
To overcome these boundaries, researchers developed a deep transfer learning model trained on whole-body PET/CT scans. The goal was to deliver fully automated tumor segmentation and outcome prediction across a wide range of cancer types.
Read the full study in the Journal of Nuclear Medicine.
How the AI model works with PET/CT imaging
The study analyzed two large datasets:
-
- 611 FDG PET/CT scans from patients with:
- Lung cancer
- Melanoma
- Lymphoma
- Head and neck cancer
- Breast cancer
- 408 PSMA PET/CT scans focused on prostate cancer
The AI system extracted radiomic features and quantified tumor burden, enabling it to:
-
- Stratify patients by risk level
- Predict treatment response
- Estimate survival rates based on tumor activity and spread
These insights move PET/CT from being a diagnostic tool to a powerful predictive imaging platform.
If you’re expanding oncology services, our Mobile PET/CT Solutions offer flexible deployment without fixed infrastructure costs.
Improving outcomes through AI-enhanced imaging
AI in PET/CT now extends far beyond simple detection. The technology supports personalized care by identifying tumor subtypes and mapping the entire disease landscape in a single scan. Notable benefits include:
-
- Predictive Biomarkers, Identify high-risk patients and tailor treatment
- Earlier Detection, Improve outcomes through timely intervention
- Therapy Optimization, Support late-stage care with accurate radiopharmaceutical dosing
Dr. Leung adds:
“This approach provides a framework that will help improve patient outcomes and survival by identifying robust predictive biomarkers, characterizing tumor subtypes, and enabling early cancer detection.”
What’s next for AI in PET/CT imaging?
The integration of AI into PET/CT workflows promises a new era of diagnostic precision and efficiency. Looking ahead, these tools will help:
- Automate and enhance scan interpretation
- Uncover molecular insights into complex disease pathways
- Improve imaging center efficiency and resource allocation
For imaging centers seeking next-generation diagnostics, our Mobile Imaging Solutions bring current-generation PET/CT directly to your facility.
Stay ahead in PET/CT innovation
Shared Medical Services continues to lead the industry in delivering mobile PET/CT systems designed to support high-precision cancer imaging. As AI transforms the diagnostic landscape, we remain committed to helping providers adapt, scale, and grow, without capital barriers.
Media Contact:
Blake Kenney
Senior Marketing Specialist
Shared Medical Services, Inc.
Phone: (608) 910-1332
Email: contactsms@sharedmed.com
Keep reading
More imaging insights
We deliver what’s next.
For more than 45 years, Shared Medical Services has been a trusted partner in mobile and interim imaging, giving hospitals, clinics, and health systems access to CT, MRI, PET/CT, and Cardiac PET/CT. From routed and parked solutions to flexible interim rentals, we bring the expertise, reliability, and service that keep imaging running.


